Stereotaxis, Inc. 8K

Stereotaxis completed its acquisition of Robocath and will integrate its technology and team to expand and enhance its endovascular robotics platform.

On July 9, 2026, Stereotaxis, Inc. (NYSE: STXS) announced that it has completed its previously announced acquisition of Robocath, a French developer of robotic technologies for interventional cardiology and neurointerventions, and will fully integrate Robocath’s technology and team into Stereotaxis to combine complementary endovascular robotic platforms, accelerate development of next-generation solutions across electrophysiology, interventional cardiology, and neurointerventions, and pursue commercial synergies in an expanded addressable market, subject to the usual integration and execution risks described in its forward-looking statements.

Filing Facts

CIK

1289340

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-032598

Alert Tier

8